Elvina Almuradova/LinkedIn
Apr 19, 2025, 16:23
Elvina Almuradova: Olaparib improved ORR and PFS in BRCA-mutated PSR ovarian cancer, but no OS benefit
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on X:
“Final SOLO3 results:
Olaparib improved ORR and PFS vs nonplatinum chemo in BRCA-mut PSR ovarian ca, but no OS benefit (HR 1.07; p=0.71).
Better OS with 2 prior lines (HR 0.83), worse with ≥3 (HR 1.33).
BRCA reversion mutations may explain.”
More posts featuring Ovarian cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 8, 2025, 13:14
Aug 8, 2025, 13:14
Aug 8, 2025, 13:11